Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib Followed by Pembrolizumab and Cisplatin in Metastatic TNBC
NCT04265872Phase 1Recruiting
- Sponsor
- Baylor Scott & White Research Institute
- Start
- Oct 2020
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bortezomib in triple-negative breast cancer (TNBC), sponsored by Baylor Scott & White Research Institute. Primary endpoint: Objective Response Rate at 18 months. Started Oct 2020; status: recruiting.
02
Drugs
bortezomib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04265872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04265872.